Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701471 | 0.85 | MEN1 (0.68) | HSD11B1MEN1KMT2AMGLL | |
| SCHEMBL4703921 | 0.85 | RBP4 (0.59) | HSD11B1 | |
| SCHEMBL27686329 | 0.84 | HSD11B1 (0.51) | HSD11B1CCR1MEN1KMT2AFNTA | |
| SCHEMBL4704705 | 0.78 | HSD11B1 (0.46) | HSD11B1TRPV1AVPR1ACCR1FNTA | |
| SCHEMBL27667271 | 0.76 | PDK2 (0.49) | HSD11B1KMT2AFNTAFNTBCNR1 | |
| SCHEMBL3062803 | 0.75 | HSD11B1 (0.91) | HSD11B1FNTAFNTB | |
| SCHEMBL27900121 | 0.74 | TRPV1 (0.55) | HSD11B1TRPV1AVPR1AMEN1KMT2A | |
| SCHEMBL4701904 | 0.74 | HSD11B1 (0.48) | HSD11B1MEN1KMT2ACNR1 | |
| SCHEMBL3436365 | 0.74 | GPR119 (0.58) | TRPV1MEN1KMT2A | |
| SCHEMBL4705022 | 0.74 | HSD11B1 (0.52) | HSD11B1KMT2AFNTAFNTBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758582-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1758582-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-01-12 | — | — | US | claimed |
| WO-2006002349-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| EP-1758582-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1758582-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-01-12 | — | — | US | disclosed |
| WO-2006002349-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885TRPV1 3010/4885AVPR1A 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.